Substance Abuse Detection
Conditions
Keywords
Substance abuse detection, Opioids abuse, Tapentadol immediate-release (IR), Oxycodone immediate-release (IR)
Brief summary
The purpose of this study is to compare the risk of shopping behavior of tapentadol immediate release with the risk of shopping behavior of oxycodone immediate release.
Detailed description
This is a retrospective (a study that looks backward in time, usually using medical records and interviews with patients) matched cohort (designated group followed or traced over a period of time) study using IMS LRx database. This database covers 65% of all retail prescriptions in the United States and includes mail service and specialty pharmacy provider prescriptions independent of the method of payment. The study will include Opioid naive patients exposed to tapentadol immediate release (IR) or oxycodone IR from July 2009 to December 2010. A naive patient is a patient who has not received an opioid of any type in the 3 months before the index date. The index date is the date of the first prescription for tapentadol IR or oxycodone IR after June 30, 2009. Patients will be followed for 1 year from their index dates. Each tapentadol IR-exposed patient will be matched to up to 4 oxycodone IR-exposed patients. Matching will allow to control in the design for potential confounding variables such as time of the exposure, geographic area, specialty of the prescriber, and age. These are variables that have been related with the risk of shopping behavior or abuse.
Interventions
DRUGTapentadol IR
Opioid naive patients exposed to tapentadol IR from July 2009 to December 2010.
DRUGOxycodone IR
Opioid naive patients exposed to Oxycodone IR from July 2009 to December 2010.
Sponsors
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Study design
Observational model
COHORT
Time perspective
RETROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Opioid naive patients (a patient who has not received an opioid of any type in the 3 months before the index date) exposed to tapentadol IR or oxycodone IR from July 2009 to December 2010 \[The index date is the date of the first prescription for tapentadol IR or oxycodone IR after June 30, 2009\]
Exclusion criteria
* Patients with use of any opioid 3 months before the index date * Patients who within 4 days on or after the index date fill a prescription for a different opioid * Patients who within 4 days on or after the index date fill a prescription for the same opioid but written by a different prescriber
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Proportion of patients who developed shopping behavior defined as patients with prescriptions with at least one day of overlap, written by ≥ 2 different prescribers and filled in 3 or more pharmacies | 12 months |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Time to first episode of shopping behavior | 12 months | — |
| The number of shopping episodes during the year of follow up | 12 months | — |
| The type of dispensing in the first episode of shopping event | 12 months | The type of dispensing in the shopping event will be classified as Only the indexed opioid Indexed opioid was involved, or Indexed opioid was not involved at all. |
Outcome results
None listed